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RNA virus infection is recognized by the RIG-I-like
receptors RIG-I and MDA5, which induce antiviral
responses including the production of type I inter-
ferons (IFNs) and proinflammatory cytokines. RIG-I
is regulated by Lys63-linked polyubiquitination, and
three E3 ubiquitin ligases, RNF125, TRIM25, and
Riplet, are reported to target RIG-I for ubiquitination.
To examine the importance of Riplet in vivo, we
generated Riplet-deficient mice. Fibroblasts, macro-
phages, and conventional dendritic cells from Riplet-
deficient animalswere defective for the production of
IFN and other cytokines in response to infection with
several RNA viruses. However, Riplet was dispens-
able for the production of IFN in response to B-DNA
and DNA virus infection. Riplet deficiency abolished
RIG-I activation during RNA virus infection, and the
mutant mice were more susceptible to vesicular
stomatitis virus infection than wild-type mice. These
data indicate that Riplet is essential for regulating
RIG-I-mediated innate immune response against
RNA virus infection in vivo.
INTRODUCTION
RNA virus infection is initially recognized by RIG-I-like receptors,
RIG-I and MDA5, which induce antiviral responses such as the
production of type I interferons (IFNs) and proinflammatory
cytokines (Yoneyama and Fujita, 2009; Takeuchi and Akira,
2010). Analyses of RIG-I and MDA5 knockout mice showed
that RIG-I is essential for type I IFN production by mouse embry-
onic fibroblasts (MEFs), conventional dendritic cells (cDCs), and
macrophages (Mfs) in response to RNA viruses such as vesicular
stomatitis virus (VSV), influenza A virus (Flu), hepatitis C virus
(HCV), Sendai virus (SeV), and Japanese encephalitis virus
(JEV). MDA5 is critical in picornavirus infection (Kato et al.,
2006; Saito et al., 2007). However, in plasmacytoid DCs
(pDCs), loss of RIG-I has no effect on viral induction of IFNs,
and TLR7 and MyD88 are required for inducing immune
responses in these cells (Diebold et al., 2004; Kato et al., 2005;
Kumar et al., 2006; Sun et al., 2006).496 Cell Host & Microbe 8, 496–509, December 16, 2010 ª2010 ElseRIG-I consists of twoN-terminalCARDs, a central DExD/Hheli-
case domain, and a C-terminal repressor domain (CTD)
(Yoneyama et al., 2004). Before viral infection, CTD of RIG-I
suppresses N-terminal CARDs (Saito et al., 2007). When the
CTD of RIG-I recognizes the 50 triphosphate-double-stranded
(ds) viral RNA, the conformation of the RIG-I protein changes,
and theN-terminal CARD triggers interactionwith its downstream
partner IPS-1 (Hornung et al., 2006; Pichlmair et al., 2006; Saito
et al., 2007; Cui et al., 2008; Takahasi et al., 2008; Rehwinkel
et al., 2010). IPS-1 contains an N-terminal CARD that interacts
with the tandemCARDsofRIG-I andaC-terminal transmembrane
domain that localizes it to the mitochondrial outer membrane
(Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu
et al., 2005). IPS-1 activates TBK1 kinase, which mediates phos-
phorylation of IRF-3, leading to its dimerization and translocation
into the nucleus (Kumar et al., 2006; Sun et al., 2006). The IRF-3
dimers, NF-kB, and AP-1 transcription factors activate type I
IFN transcription (Honda et al., 2005). The secreted type I IFNs
activates the IFNAR, which leads to phosphorylation and nuclear
translocation of STAT1 (Akira et al., 2006; Honda et al., 2006).
RIG-I is regulated by ubiquitination. Three E3 ubiquitin ligases,
RNF125, TRIM25, and Riplet, target RIG-I (Arimoto et al., 2007;
Gack et al., 2007; Oshiumi et al., 2009). RNF125 functions as
a negative regulator for RIG-I signaling and mediates Lys48-
linked polyubiquitination of RIG-I, leading to protein degradation
by the proteasome (Arimoto et al., 2007). On the other hand,
TRIM25 and Riplet function as positive regulators for the
signaling. TRIM25 mediates Lys63-linked polyubiquitination at
Lys172 of RIG-I CARDs (Gack et al., 2007). Lys63-linked
polyubiquitination induces interaction between RIG-I and IPS-1
CARDs, leading to the activation of signaling (Gack et al.,
2007, 2008). However, there are several reports that describe
other models. First, Zeng et al. developed an in vitro reconstitu-
tion system of the RIG-I pathway (Zeng et al., 2010). Using this
system, they showed that Lys172 of RIG-I CARDs is required
for binding to the Lys63-linked polyubiquitin chain (Zeng et al.,
2010). They postulated that polyubiquitin binding and not ubiqui-
tinmodification is required for RIG-I activation (Zeng et al., 2010).
In their model, unanchored polyubiquitin chains are responsible
for RIG-I activation. However, they did not rule out the possibility
that ubiquitination of some signaling proteins may contribute to
RIG-I activation (Zeng et al., 2010). Second, Fujita T and his
colleagues reported that residue 172 of mouse RIG-I is not Lys
but Gln and human RIG-I K172R mutant was normally activated
by SeV infection in RIG-I KO MEFs (Shigemoto et al., 2009).vier Inc.
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ubiquitination of RIG-I CTD and CARDs (Gao et al., 2009;
Oshiumi et al., 2009). This polyubiquitination promotes RIG-I
activation and its antiviral activity in human cells (Horner and
Gale, 2009; Nakhaei et al., 2009; Takeuchi and Akira, 2010;
Yoneyama and Fujita, 2010); however, in vivo evidence is absent.
Type I IFNs are mainly produced by DCs or Mf in vivo, and RIG-I
is essential for type I IFN production in cDC and Mf (Kato et al.,
2005; Sun et al., 2006; Kumagai et al., 2007). The role of Riplet
in these cells also has not yet been examined. Both TRIM25
and Riplet proteins mediate Lys63-linked polyubiquitination of
RIG-I, and thus Gao et al. suggested that Riplet may be
a complementary factor of TRIM25 for RIG-I activation (Gao
et al., 2009). Therefore, it is not known whether Riplet is essential
for RIG-I activation. To address these issues, we generated
Riplet knockout mice. Our analysis revealed that Riplet is essen-
tial for the RIG-I activation and innate immune responses against
viral infection in vivo.
RESULTS
Ubiquitous Expression of Riplet mRNA
First, we examined mouse Riplet mRNA expression by quantita-
tive PCR (qPCR), and found it to be ubiquitously expressed in
various tissues, MEFs, bone marrow-derived DCs (BM-DCs),
and Mf (BM-Mf) (Figure 1A, left panel). Furthermore, we have
previously shown that human Riplet mRNA is expressed in
various tissues. When we examined the expression of Riplet
mRNA in human DCs, it was observed in human DCs as in
HeLa cells (Figure 1A, right panel). These data indicate that Riplet
is expressed in various tissues and cells that are able to produce
type I IFNs.
Generation of Riplet-Deficient Mice
Previously, we have shown that Riplet is a positive regulator for
RIG-I-mediated signaling, and it mediates Lys63-linked polyubi-
quitination of RIG-I. However, the functional role of Riplet in vivo
remains unclear. To investigate the role of Riplet in vivo, we
generated Riplet-deficient (Riplet/) mice by homologous
recombination of embryonic stem cells (ESCs) (Figure 1B). We
confirmed the target disruption of Riplet without deletion outside
the targeted region (Figure 1C, and see Figures S1A and S1B
available online). Riplet mRNA expression was abolished in
Riplet/ cells (Figures 1E and 1F), and the knockout of Riplet
did not affect the expression of other genes, such as RIG-I,
MDA5, IPS-1, TICAM-1, TLR3, and TRIM25, which are involved
in type I IFN production (Figure 1F). The mutant mice were
born at the Mendelian ratio from Riplet+/ parents (Figure 1D),
and they developed and bred normally. These mice displayed
no apparent abnormalities up to 7 months of age. Mutations in
the human Riplet/RNF135 gene cause the overgrowth syndrome
(Douglas et al., 2007). We did not observe any overgrowth
phenotypes in Riplet+/ and Riplet/ mice. Next, we examined
the composition of CD4-, CD8-, CD11c-, and/or PDCA1-positive
cells in the spleen, and found no difference between wild-type
and Riplet/ mice (Figures S1C and S1D). Induction of cDC
fromBM in the presence of GM-CSFwas also normal inRiplet/
mice (Figure S1E). Therefore, the mouse Riplet gene is dispens-
able for development.Cell Host &Riplet–/– Embryonic Fibroblasts Are Defective in Innate
Immune Responses against RNA Viruses
Riplet is a positive regulator for RIG-I-mediated signaling. In
mouse fibroblast, VSV and Flu are mainly recognized by RIG-I
(Kato et al., 2006). Furthermore HCV 30UTR RNA is also recog-
nized by RIG-I (Saito et al., 2008). Therefore, we first examined
the expression of type I IFNs, IFN-inducible gene IP-10, and
Ccl5 in MEFs after HCV 30UTR dsRNA transfection or infection
with VSV or Flu. The induction of mRNA of IFN-a2, -b, IP-10,
and Ccl5 in response to VSV or Flu was abrogated in Riplet/
MEFs (Figures 2A–2D). In addition, transfection of low concen-
tration of HCV 30UTR dsRNA (0.05–0.2 mg/well) also failed to up-
regulate IFN-a2, -b, and IFN-inducible genes in Riplet/ MEFs
(Figures 2A–2D).
Single-stranded (ss) RNA, which is synthesized by T7 RNA
polymerase in vitro, induced lower IFN-b expression than
dsRNA (Figure S2A). The induction of IFN-b mRNA by HCV
30UTR ssRNAwas also abolished inRiplet/MEFs (Figure S2A).
Although the induction of IFN-bmRNA in response to VSV infec-
tionwas abrogated inRiplet/MEFs even at high (moi = 5) or low
multiplicities of infection (moi = 0.2 or 1), the induction of IFN-b
mRNA in response to high concentration of HCV dsRNA
(0.8 mg/well) was detected in Riplet/MEFs (Figures S2C–S2K).
Therefore, RIG-I does not require Riplet function in the presence
of large amounts of naked viral RNA in the cytoplasmic region.
Recently, Onoguchi et al. reported that type III IFN, IFN-l,
induction was RIG-I dependent during viral infection (Onoguchi
et al., 2007). The induction of IFN-l mRNA in response to VSV
was also abrogated in Riplet/ MEFs (Figure S2B).
Next, we examined type I IFNs or IL-6 levels in culture super-
natants after viral infection or HCV 30UTR RNA transfection (low
concentration condition). The production of IFN-a, -b, and IL-6 in
culture supernatants was abrogated in Riplet/ MEFs (Figures
3A–3C). Next, we analyzed the contribution of Riplet to the
antiviral response.WhenMEFswere infectedwith VSV at various
mois, cytopathic effects (CPEs) were more severe in Riplet/
than in wild-type MEFs (Figure 3D). These results demonstrate
that Riplet plays a critical role in the elimination of RNA virus
infection by induction of IFN responses.
Riplet Is Dispensable for the Production of Type I IFN
Induced by B-DNA and HSV-1 Infection
Cytoplasmic B-form double-stranded DNA (dsDNA) stimulates
the cells to induce type I IFNs and IFN-inducible genes (Ishii
et al., 2006). TBK1 is required for type I IFN induction by dsDNA
(Ishii et al., 2008). Although immortalized MEFs require RIG-I for
type I IFNs production by dsDNA stimulation, primary MEFs do
not require IPS-1, which is a RIG-I adaptor, for type I IFNs
production by dsDNA (Kumar et al., 2006; Chiu et al., 2009).
We examined the expression of IFN-b and IP-10 mRNA by
dsDNA stimulation in primary wild-type and Riplet/ MEFs.
IFN-b and IP-10 mRNA were detected in Riplet/ MEFs by
dsDNA transfection similar to that detected in wild-type MEFs
(Figures 4A and 4B).
Next, we examined IFN-b mRNA expression during infection
with DNA virus, HSV-1. Wild-type and Riplet/ MEFs were
infectedwith HSV-1, and IFN-bmRNA expression was examined
by RT-qPCR. IFN-b expression in Riplet/ MEFs was compa-
rable to that in wild-typeMEFs (Figure 4C). Taken together, theseMicrobe 8, 496–509, December 16, 2010 ª2010 Elsevier Inc. 497
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Figure 1. Targeted Disruption of the Murine Riplet Gene
(A) Riplet mRNA expression in mouse tissues and cells or human cells. RT-qPCR was performed to measure Riplet mRNA, and each sample was normalized to
b-actin (mouse) or GAPDH (human). Data are shown as means ±SD and are representative of three independent experiments.
(B) Structure of the mouse Riplet gene, targeting vector, and disrupted gene. Closed boxes indicate the coding exon of Riplet, and hatched boxes indicate the
Neo or TK gene coding region. The primer sets for PCR are shown by arrows.
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Riplet Is Essential for RIG-I-Mediated Signalingdata indicate that Riplet-dependent RIG-I activation is dispens-
able for type I IFN and IFN-inducible genes mRNA expression by
cytoplasmic DNA in primary MEFs. This is consistent with
previous studies reporting that the IPS-1-dependent pathway
is dispensable for type I IFN production by cytoplasmic dsDNA
stimulation (Kumar et al., 2006).
Riplet Is Essential for Triggering the RIG-I Signaling
Pathway
We further examined the role of Riplet in RIG-I-mediated
signaling during RNA virus infection. In RIG-I-mediated
signaling, induction of type I IFNs and proinflammatory cytokines
requires the activation of transcription factor IRF3. IRF3 is
phosphorylated by TBK1 and IKK-3. Phosphorylated IRF3
induces IFN-b gene expression. IFN-b produced subsequently
stimulates the JAK-STAT pathway to amplify the responses.
To determine the role of Riplet in signaling pathway activation,
we analyzed IRF3 and STAT1 activations after VSV infection in
Riplet/ MEFs. VSV-induced dimerization of IRF3 and VSV- or
Flu-induced pohsphorylation of STAT1 were abrogated in
Riplet/ MEFs (Figures 3E and 3F). These results demonstrate
that Riplet is essential for activating the transcription factors
that work early phase of RNA virus infection.
In the absence of viral infection, RIG-I CTD suppressed
N-terminal CARDs (Saito et al., 2007). After viral infection,
RIG-I CTD binds to viral RNA, leading to conformational changes
(Saito et al., 2007). Later, RIG-I CARDs undergo TRIM25-medi-
ated polyubiquitination and associate with IPS-1 CARD
(Gack et al., 2007, 2008). When we tested the effect of Riplet
on RIG-I activation, the full-length RIG-I protein with CTD failed
to activate the IFN-b promoter in Riplet/ MEFs (Figure 5A);
however, promoter activation by the expression of RIG-I
CARDs without CTD was normal in Riplet/ MEFs (Figure 5B).
These data indicate that Riplet is required for the activation of
full-length RIG-I, but not for the activation of RIG-I CARDs
without CTD. Next, we performed complementation assays.
Immortalized Riplet/ MEFs were transfected with an empty-,
RIG-I-, or RIG-I-5KA mutant-expressing vector together with or
without Riplet-expressing vector. The RIG-I-5KAmutant harbors
mutations in five C-terminal Lys residues that are important for
Riplet-mediated ubiquitination (Oshiumi et al., 2009). In the
Riplet/ cell line, RIG-I was not activated by HCV RNA stimula-
tion, and Riplet expression led to the activation of wild-type RIG-I
(Figure 5C). The deletion of the Riplet RING finger domain, which
is the catalytic domain of ubiquitin ligase, abolished RIG-I activa-
tion (Figure 5D). Unlike wild-type RIG-I, Riplet expression failed
to activate the RIG-I-5KA mutant protein (Figure 5C). The activa-
tions of wild-type and mutant RIG-I were correlated with its
polyubiquitination (Figure S3A). Although the RNA binding
activity was weakly reduced by the 5KA mutation, the pull-
down assay showed that RIG-I-5KA mutant bound to dsRNA(C) PCR of mouse tail. Genomic DNA was extracted from wild-type, Riplet+/, or
(D) Genotype analyses of offspring from heterozygote intercrosses. Chi-square go
tically significant (p > 0.1).
(E) RT-PCR of MEFs. Total RNA from wild-type and Riplet/ MEFs were extrac
(F) Riplet, IPS-1 MDA5, RIG-I, TICAM-1, TLR3, and TRIM25 expression in MEFs.
RT-qPCR to determine mRNA expression. Expression of the indicated gene mRN
and are representative of three independent experiments. ‘‘NS’’ indicates no sta
See also Figure S1 and Table S1.
Cell Host &(Figure S3B). Next, we examined ligand-independent RIG-I acti-
vation by overexpression of Riplet. Overexpression of Riplet in
HEK293 cells activated RIG-I in the absence of RIG-I ligand,
such as viral RNA (Figure S3C). This ligand-independent
activation of RIG-I by Riplet overexpression was also abolished
by the 5KA mutation (Figure S3C). In addition, we examined
the polyubiquitination of exogenously expressedRIG-I CTD frag-
ment. Polyubiquitination of RIG-I CTD fragment was increased
by overexpression of Riplet (Figure 5M), and was reduced by
overexpression of the dominant-negative form of Riplet (Riplet
DN) (Figure 5N). Polyubiquitination of RIG-I CTD fragment was
not detected in Riplet-deficient cells (R3T cells); however,
expression of Riplet led to polyubiquitination of RIG-I CTD frag-
ment (Figure 5O). These data are consistent with our previous
report (Oshiumi et al., 2009). Taken together, these data indicate
that Riplet-dependent polyubiquitination of RIG-I is important for
RIG-I activation.
Previously, we showed that Riplet is not involved in MDA5-
mediated signaling. IFN-b promoter activation by MDA5 overex-
pression was normal in Riplet/ MEFs (Figure 5E). Transfection
of poly(I:C), which is recognized by MDA5, induced IFN-b, IL-6,
and IP-10 expression in both wild-type and Riplet/ MEFs
(Figures 5F–5H). In addition, stimulation with lipopolysaccharide
(LPS), which is a TLR4 ligand, normally induced expression of
these cytokines in Riplet/ MEFs (Figures 5I–5K). Furthermore,
IL-6 production in culture medium in response to LPS was
normal in Riplet/ MEFs (Figure 5L). Taken together, these
data indicate that Riplet is essential for the RIG-I-mediated
type I IFN or IL-6 production upon viral infection in nonprofes-
sional immune cells like fibroblasts, but is not required for
MDA5- or TLR4-mediated signaling.
Riplet Is Required for Antiviral Innate Immune
Responses in Conventional Dendritic Cells
and Macrophages
Weexaminedwhether Riplet is required for the induction of type I
IFN in DCs or Mf. DCs play a pivotal role in bridging innate and
adaptive immune responses, and can be classified into cDCs
and pDCs, the latter producing high levels of type I IFNs. Mfs
also produce type I IFN. We induced cDCs from BM cells in
the presence of GM-CSF (BM-DC). Twenty-four hours after
VSV or Flu infection, cDCs of wild-type mice produced
IFN-a, -b, and IL-6 (Figures 6A–6F). In contrast, the cDCs of
Riplet/ mice showed severely impaired IFN-a, -b, or IL-6
production during VSV or Flu infection (Figures 6A–6F). When
the cDCs were stimulated with a TLR4 ligand, such as LPS,
IFN-b or IL-6 production in Riplet/ cDCs was almost normal
(Figures S4A and S4B), indicating that Riplet is dispensable for
LPS-induced cytokine production in cDCs.
Then we tested M-CSF-induced BM-Mf. Wild-type Mf
produced IFN-a, -b, and IL-6 after VSV or Flu infection (FiguresRiplet/ mice tails and PCR was performed using primers shown in (B).
odness-of-fit test indicated that deviation fromMendelian ratio was not statis-
ted and subjected to RT-PCR to determine Riplet mRNA expression.
Total RNA from wild-type and Riplet/ MEFs were extracted and subjected to
A was normalized to b-actin mRNA expression. Data are shown as means ±SD
tistically significant difference between the two samples.
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Figure 2. Abolished Responses to RNA Virus Infection in Riplet–/– Fibroblasts
Wild-type or Riplet/ MEFs were infected with VSV or influenza A virus (Flu), and total RNA was extracted at the indicated times. Short HCV 30UTR dsRNA was
transfected into wild-type orRiplet/MEFs, and total RNAwas extracted after 24 hr. Extracted RNAwas subjected to RT-qPCR to determine IFN-b (A), IP10 (B),
Ccl5 (C), or IFN-a2 (D) expression. Expression of each sample was normalized to b-actinmRNA expression. Data are shown asmeans ±SD and are representative
of three independent experiments. *p < 0.05, **p < 0.01 (t test).
See also Figure S2 and Table S1.
Cell Host & Microbe
Riplet Is Essential for RIG-I-Mediated Signaling
500 Cell Host & Microbe 8, 496–509, December 16, 2010 ª2010 Elsevier Inc.
0           0.001        0.01          0.1             1
Riplet -/-
WT
MEF VSV infection (36 hr)
VSV    -      +      -      +
(VSV MOI=5)
Riplet -/-     WT
Monomer
Dimer
MOI
BA
350
300
250
200
150
100
50
0
IL
-6
 [p
g/m
l] WTRiplet -/-
IF
N
- α
 
[pg
/m
l] WTRiplet -/-
1200
1000
800
600
400
200
0
HCV 3’ 
UTR RNA
IF
N
- α
 
[pg
/m
l]
IF
N
- β 
[pg
/m
l]
300
250
200
150
100
50
0
WT
Riplet -/-
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
N
.D
.
*
* MEF
MEF
MEFMEF
DC
FE
p-STAT1
STAT1
β-actin
Riplet -/-           WT
-    VSV  Flu     -   VSV Flu
(MOI=1, 20hr)
300
250
200
150
100
50
0 N
.D
.
-
-         VSV      Flu
WT
Riplet -/-
MEF
-    HCV3’  VSV    Flu
   UTR RNA
-    HCV3’   VSV   Flu
   UTR RNA
Figure 3. Role of Riplet in Antiviral Responses in Fibroblasts
(A–C) Wild-type or Riplet/MEFs were infected with VSV or Flu or transfected with short HCV 30UTR dsRNA. Amounts of IFN-a (A), -b (B), and IL-6 (C) in culture
supernatants were measured by ELISA after 24 hr. Data are shown as means ±SD and are representative of three independent experiments. *p < 0.05, **p < 0.01
(t test).
(D) Wild-type or Riplet/ MEFs were infected with VSV at the indicated moi, and after 36 hr MEFs were fixed with formaldehyde and stained with crystal violet.
(E) Wild-type or Riplet/ MEFs were infected with VSV at moi = 5, and after 9 hr cell lysates were prepared and analyzed by native PAGE. IRF-3 proteins were
stained with anti-IRF3 antibody.
(F)Wild-type orRiplet/MEFswere infectedwith VSV or Flu at moi = 1, and after 20 hr cell lysates were prepared. The sampleswere analyzed by SDS-PAGE and
western blotting. They were stained with anti-STAT1, phospho-STAT1, or b-actin antibodies.
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Figure 4. Role of Riplet in Type I IFN Production Induced by Cyto-
plasmic dsDNA
(A and B) Wild-type and Riplet/ MEFs were transfected with the indicated
amounts of dsDNA (Salomon sperm DNA) using the Lipofectamine 2000
reagent. Nine hours after the transfection, IFN-b (A) and IP-10 (B) mRNA
expression was determined by RT-qPCR. Data are shown as means ±SD
and are representative of three independent experiments.
(C) Wild-type and Riplet/ MEFs were infected with HSV-1 at moi = 4, and
IFN-b mRNA expression at the indicated times was examined by RT-qPCR.
Data are shown as means ±SD and are representative of three independent
experiments.
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Riplet knockout mice (Figures 6A–6F). Peritoneal Mf were
isolated from wild-type and Riplet/ mice. Knockout of Riplet
reduced type I IFN production from peritoneal Mfs during VSV
infection (Figures S4C and S4D).
We next generated Flt3L-induced DCs (Flt3L-DCs), which
contain pDCs. Akira and his colleagues previously showed that
the knockout of RIG-I or IPS-1 does not reduce type I IFN and
IL-6 production by Flt3L-DCs, because RIG-I is dispensable for
cytokine production in pDCs (Kato et al., 2005). The Flt3L-DCs
of Riplet/ mice produced normal amounts of IFN-a, -b, and
IL-6 during Flu infection (Figures 6A–6F). This is consistent with
the notion that Riplet is essential for the RIG-I-mediated type I
IFNs and IL-6 production. Although the IFN-a levels in the culture
medium after VSV infection were comparable with those in wild-
type and Riplet/ mice, Flt3L-DCs of Riplet/ mice produced
less IL-6 compared with that produced by wild-type mice
through an unknown mechanism (Figure 6C).
Next, we examined type I IFN production during SeV infection.
SeV infection induced IFN-a and -b productions from wild-type
BM-DC, and the knockout of Riplet reduced IFN-a and -b
productions from BM-DC (Figures S4E–S4J). Wild-type
Flt3L-DC produced IFN-a after SeV infection, and the knockout
of Riplet did not reduce IFN- a production from Flt3L-DC (Figures
S4E–S4J).
Riplet Is Essential for Antiviral Immune Defense In Vivo
To investigate the role of Riplet in antiviral responses in vivo,
wild-type and Riplet/ mice were injected intraperitoneally
with wild-type VSV, and sera were collected to measure type I
IFN and IL-6 levels. IFN-a, -b, and IL-6 levels in sera were
markedly reduced in Riplet/ mice compared to in wild-type
mice (Figures 7A and 7B, and Figure S5A). Next, wild-type and
Riplet/ mice were intranasally infected with VSV, and type I
IFN levels in their sera were measured. At early time points,
IFN-a and -b production was reduced in Riplet/ mice
compared to wild-type mice (Figures 7C and 7D); however,
cytokine levels were comparable at later time points (Figures
S5B and S5C). Previously, Ishikawa et al. observed that the
knockout of STING gene, which is involved in RIG-I-dependent
signaling, leads to reduction of type I IFN at early time points
and relatively less reduction at later time points (Ishikawa and
Barber, 2008; Ishikawa et al., 2009).
To determine if Riplet deficiency affects the survival of mice
after VSV infection, the mice were intranasally infected with
VSV, and their survival was monitored. Wild-type mice
survived VSV infection; however, Riplet/ mice were suscep-
tible to VSV infection (Figure 7E). The viral titer in Riplet/
mice brains 7 days after infection was higher than in wild-type
mice (Figure 7F). These data indicate that Riplet plays a key
role in the host defenses against VSV infection in vivo, and
type I IFN production at early time points is important for host
defenses.
DISCUSSION
In this study, we presented genetic evidence that Riplet is indis-
pensable for antiviral responses in MEFs, BM-Mf, and BM-DCs,
but not in Flt3L-DCs. The cell-type-specific requirement of Ripletvier Inc.
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Figure 5. Role of Riplet in the RIG-I-Dependent Pathway
(A) Expression vector of full-length RIG-I and reporter plasmids were transfected into wild-type or Riplet/ MEFs with or without HCV 30UTR short dsRNA, and
after 24 hr IFN-b promoter activation was examined by reporter gene assay. Data are shown as means ±SD and are representative of three independent exper-
iments. *p < 0.05 (t test).
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Riplet Is Essential for RIG-I-Mediated Signalingis similar to that of RIG-I. Previously, we showed that Riplet binds
to RIG-I and mediates Lys63-linked polyubiquitination of RIG-I
(Oshiumi et al., 2009). Genetic evidence in this study revealed
that Riplet function is essential for RIG-I-dependent type I IFN
production. Knockout of Riplet reduced type I IFN production
in vivo during the early phase of VSV infection, and Riplet/
mice were susceptible to VSV infection. Taken together, our
results provide genetic evidence that Riplet is essential for
RIG-I-dependent antiviral immune response in vivo. Most
RIG-I/ embryos were lethal at embryonic days 12.5–14.0 in
some strain backgrounds (Kato et al., 2005). However, we could
not observe any developmental defect in Riplet knockout mice
as far as we examined.
Previously, Chen and his colleagues independently isolated
Riplet and named it REUL (Gao et al., 2009). They reported
that REUL/Riplet binds to RIG-I CARDs but not to CTD
(Gao et al., 2009). Furthermore, they reported that REUL/Riplet
mediates Lys63-linked polyubiquitination of Lys172 of RIG-I
CARDs in a manner similar to TRIM25 (Gack et al., 2007; Gao
et al., 2009). Although they did not show any expression profile
data for Riplet and TRIM25, they mentioned that TRIM25 and
Riplet have different distribution patterns, and thus hypothesized
that REUL/Riplet is a complementary factor of TRIM25 and is
required for RIG-I activation in cells that do not express
TRIM25 (Gao et al., 2009). However, our genetic evidence is
not consistent with their hypothesis, because Riplet is essential
for RIG-I activation in MEFs that express TRIM25. Previously,
Gack et al. showed that knockout of TRIM25 alone abolished
RIG-I activation inMEFs (Gack et al., 2007). Therefore, null muta-
tion in either Riplet or TRIM25 abolishes RIG-I activation. This
genetic evidence indicates that Riplet can mediate polyubiquiti-
nation of RIG-I Lys residues that are not ubiquitinated by
TRIM25. This means that Riplet functions differently than
TRIM25 in RIG-I activation.
We isolated Riplet cDNA by yeast two-hybrid screening using
the C-terminal region of RIG-I (Oshiumi et al., 2009). Because
the yeast genome does not encode RIG-I, the interaction indi-(B) Expression vector for the two RIG-I N-terminal CARDs were transfected into w
activation was examined by the reporter gene assay. Data are shown asmeans ±S
statistically significant.
(C) Empty, wild-type RIG-I-, or RIG-I-5KAmutant-expressing vectors were transfe
ing vector. Cells were stimulated with HCV 30UTR short dsRNA, and reporter ge
(D) Empty or wild-type RIG-I-expressing vectors were transfected into the Riplet
dRING)-expressing vector. Cells were stimulated with HCV 30UTR short dsRNA,
(E) Empty or MDA5-expressing vectors was transfected into wild-type or Riplet
vation was examined by the reporter gene assay.
(F–H) Of poly(I:C), 0.8 mg was transfected into wild-type or Riplet/ MEFs. Twen
jected to RT-qPCR to determine IFN-b (F), Ccl5 (G), and IP10 (H) expression. Ex
(I–K) Wild-type or Riplet/ MEFs were stimulated with 1 mg of LPS. Total RNA w
IFN-b (I), IL-6 (J), or IP-10 (K) expression.
(L) Wild-type or Riplet/ MEFs were stimulated with LPS, and after 24 hr the am
(M) HEK293FT cells were transfected with Riplet, FLAG-tagged RIG-I-CTD, and H
fection, cell lysates were extracted and immunoprecipitation was carried out with a
were analyzed by SDS-PAGE, and western blotting was performed using anti-HA
The plasmids are described previously (Oshiumi et al., 2009).
(N) Expression vector of dominant negative form of Riplet (Riplet DN) was transfec
CTD and HA-tagged ubiquitin. Cells were stimulated with dsRNA. Ubiquitination
(O) R3T cells were transfected with Riplet, FLAG-tagged RIG-I-CTD, and HA-tag
Ubiquitination of RIG-I-CTD was detected as in (M).
See also Figure S3.
504 Cell Host & Microbe 8, 496–509, December 16, 2010 ª2010 Elsecates the direct binding of Riplet to the RIG-I C-terminal region.
The interaction between RIG-I CTD and Riplet has also been
confirmed by immunoprecipitation assays in human cells
(Oshiumi et al., 2009). Moreover, we have shown that Riplet
expression leads to Lys63-linked polyubiquitination of RIG-I
CTD (Oshiumi et al., 2009). Recently, Zheng et al. showed that
RIG-I CARDs has the ability to bind to polyubiquitin chains
(Zeng et al., 2010). We have carefully detected Riplet-mediated
polyubiquitination of RIG-I C-terminal region without CARDs,
under high-salt conditions, in which many protein-protein
interactions were abolished (Oshiumi et al., 2009). Therefore,
we proposed the hypothesis that Riplet mediates Lys63-linked
polyubiquitination of RIG-I CTD (Oshiumi et al., 2009). Thismodel
can explain the genetic evidence that Riplet is essential for RIG-I
activation in MEFs that express TRIM25. Gack et al. showed that
K172R mutation alone caused near-complete loss of ubiquitina-
tion of the human RIG-I CARDs (Gack et al., 2007). Because
residue 172 of mouse RIG-I is not Lys but Gln (Shigemoto et al.,
2009), Riplet/Reul does not ubiquitinate residue 172 of mouse
RIG-I. Based on the previous studies and our current data, we
prefer the interpretation that Riplet activates RIG-I through poly-
ubiquitination of RIG-I CTD.However, this interpretation does not
exclude the possibility that Riplet ubiquitinates both CTD and
CARDs of RIG-I (Gao et al., 2009; Oshiumi et al., 2009).
Previously, we showed that Lys849, -851, -888, -907, and -909
are critical residues in Riplet-mediated RIG-I CTD ubiquitination
(Oshiumi et al., 2009). These five Lys residuse are close to the
dsRNA binding sites of RIG-I CTD (Takahasi et al., 2008), and
the 5KA mutation weakly reduced RNA binding activity of
RIG-I. Therefore, it is possible that the 5KA mutation abrogate
activation and polyubiquitination of RIG-I by reducing RNA
biding activity of RIG-I. However, this possibility is weakened
by following observations. First, the 5KA mutation caused
near-complete loss of RIG-I activation, but the RIG-I-5KAmutant
protein still possessed RNA binding activity. Second, overex-
pression of Riplet led to RIG-I activation in the absence of dsRNA
in HEK293 cells, and this ligand-independent activation of RIG-Iild-type or Riplet/MEFs together with reporter plasmids, and IFN-b promoter
D and are representative of three independent experiments. ‘‘NS’’ indicates not
cted into theRiplet/MEF cell line together with or without the Riplet-express-
ne assay was performed as described in (A).
/ MEF cell line together with empty, wild-type Riplet, or Riplet mutant (Riplet
and the reporter gene assay was performed as described in (A).
/ MEFs together with reporter plasmids, and after 24 hr IFN-b promoter acti-
ty-four hours after transfection, total RNA was extracted from MEFs and sub-
pression in each sample was normalized to the b-actin mRNA expression.
as extracted at the indicated times and subjected to RT-qPCR analysis for of
ount of IL-6 in culture supernatants was measured by ELISA.
A-tagged ubiquitin (HA-Ub) expression vectors. Twenty-four hours after trans-
nti-FLAG antibody as previously described (Oshiumi et al., 2009). The samples
polyclonal antibody (Ub) and anit-Flag M2 monoclonal antibody (RIG-I-CTD).
ted into HEK293FT cells together with expression vector of FLAG-tagged RIG-I
of RIG-I CTD was detected as in (M).
ged ubiquitin (HA-Ub) expression vectors. Cells were stimulated with dsRNA.
vier Inc.
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Figure 6. Role of Riplet in Responses to VSV or Flu Infection in Bone Marrow-Derived Cells
GM-DCs, BM-Mf, or Flt3L-DCs were induced from BM-derived cells in the presence of GM-CSF, M-CSF, or Flt3L and infected with VSV or influenza A virus at
moi = 1. Twenty-four hours after viral infection, amounts of IFN-b (A and D), -a (B and E), and IL-6 (C and F) in culture supernatants were measured by ELISA. Data
are shown as means ±SD and are representative of two independent experiments. *p < 0.05 (Student’s t test). NS indicates not statistically significant.
See also Figure S4.
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Riplet Is Essential for RIG-I-Mediated Signalingby overexpression of Riplet was also abolished by the 5KAmuta-
tion. These data support our model. However, we do not exclude
the possibility that other Lys residues of RIG-I are ubiquitinated
by Riplet, because we have not yet directly detected polyubiqui-
tinated residues of RIG-I CTD by mass spectrometory analysis.
Further in vitro studies are required to determine the polyubiqui-
tination sites and to reveal precise RIG-I regulatory mechanisms
by Riplet-mediated Lys63-linked polyubiquitation.Cell Host &In general, E3 ubiquitin ligase targets several types of proteins.
Therefore, it is possible that Riplet targets other proteins.
Previous work has shown that Riplet binds to the Trk-fused
gene (TFG) protein (Suzuki et al., 2001). The TFGprotein interacts
with TANK and NEMO, which are involved in the NF-kB pathway
(Miranda et al., 2006). Although NEMO is involved in IPS-1-medi-
ated signaling, RIG-I CARDs- or MDA5-mediated signaling was
normal in Riplet/ MEFs. Therefore, interaction between RipletMicrobe 8, 496–509, December 16, 2010 ª2010 Elsevier Inc. 505
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Figure 7. Role of Riplet in Antiviral Responses In Vivo
(A and B) Wild-type orRiplet/mice were injected intraperitoneally with 13 106 pfu of VSV. Amounts of IFN-a (A) and IL-6 (B) in mouse serumwere measured by
ELISA. Data are shown as mean ±SD of samples obtained from three wild-type and three Riplet / mice at each time point. *p < 0.05 (Student’s t test). ‘‘ND’’
indicates not detected.
(C and D) Wild-type and Riplet/mice were infected intranasally with 43 105 pfu of VSV. Amounts of IFN-a (C) and IFN-b (D) in mouse serum were measured by
ELISA.
(E) Wild-type and Riplet/mice were infected intranasally with 23 106 pfu of VSV andmicemortality was observed for 14 days (*p < 0.05 between wild-type and
Riplet/ mice, log rank test).
(F) Wild-type and Riplet/ mice were infected intranasally with 2 3 106 pfu of VSV, and sacrificed for their tissues on day 7 after infection. Titers in brain were
determined by the plaque assay. Viral titers in brains of wild-type mice were below 100 pfu/g, and thus not detected (ND). Data are shown as means ±SD (n = 3).
See also Figure S5.
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Cell Host & Microbe
Riplet Is Essential for RIG-I-Mediated Signalingand TFG protein is not required for RIG-I-mediated signaling.
However, since TFG is involved in tumorigenesis (Miranda
et al., 2006), Riplet may be involved in human tumorigenesis.
Several viral proteins inhibit RIG-I-mediated signaling. For
example, Flu NS1 inhibits TRIM25 and HCV NS3/4A cleaves
IPS-1 (Meylan et al., 2005; Gack et al., 2009). Therefore, Riplet
may be inhibited by viral proteins. Indeed, our pilot study indi-
cated that the Riplet protein is disrupted in human hepatocyte
cell lines carrying a full-length HCV replicon. RIG-I is involved
in innate immune responses against various viruses. In this
study, we showed that Riplet is required for innate immune
responses against VSV, Flu, and SeV. Therefore, Riplet is also
expected to be involved in innate immune responses against
other viruses that are recognized by RIG-I.
EXPERIMENTAL PROCEDURES
Generation of Riplet-Deficient Mice
The Riplet gene was amplified by PCR using genomic DNA extracted from
ESCs by PCR. The targeting vector was constructed by replacing the second
and third exons with a neomycine-resistance gene cassette (Neo), and
a herpes simplex virus thymidine kinase (HSV-TK) driven by PGK promoter
was inserted into the genomic fragment for negative selection. After the target-
ing vector was transfected into 129/Sv mice-derived ESCs, G418 and
gancyclovir doubly resistant colonies were selected and screened by PCR.
The targeted cell line was injected in C57BL/6 blastocysts, resulting in the birth
of male chimeric mice. These mice were then crossed with 129/Sv mice to
obtain heterozygous mutants. The heterozygous mutants were intercrossed
to obtain homozygous Riplet/ mice.
Cells, Viruses, and Reagents
Wild-type and Riplet/ MEFs were prepared from day 12.5–13.5 embryos.
Riplet/ MEFs were immortalized with large T antigen and named R3T cell
line. BM cells were prepared from 5- to 10-week-old mice. VSV Indiana strain
was provided by A. Takada (Hokkaido University). VSV was amplified using
Vero cells and the viral titer was determined by the plaque assay. Flu (PR8
strain) and SeV (HVJ strain) was provided by Y. Sakoda (Hokkaido University).
HSV-1 strain was provided by K. Kondo (The JIKEI University). Anti-mouse
IRF3 antibody was purchased from Zymed. Anti-phospho-STAT1 antibody
was purchased from Cell Signaling and anti-STAT1 antibody from Santa
Cruz. Salomon sperm dsDNA was purchased from Invitrogen. To determine
the viral titer in the brain, the mice were sacrificed, and the brain was
aseptically removed and frozen at 80C. The brain was homogenized in
1 ml of PBS on ice, and the titer was determined by plaque assay.
Preparation of Viral Double-Stranded RNA
cDNA of the HCV 30UTR region was amplified from total RNA of the HCV geno-
type 1b full-length replicon using primers HCV-F1 and HCV-R1, and then
cloned in the pGEM-T Easy Vector. The primer set sequences were HCV-F1,
CTCCAGGTGAGATCAATAGG; and HCV-R1, CGTGACTAGGGCTAAGATGG.
RNA was synthesized using T7 and SP6 RNA polymerases. Template DNA
was digested by DNase I, and RNA was purified using TRIZOL (Invitrogen)
according to manufacturer’s instructions.
Quantitative PCR
For qPCR, total RNAwas extractedwith TRIZOL (Invitrogen) and 0.5 mg of RNA
was reverse-transcribed using the High Capacity cDNA Transcription Kit (ABI)
with random primers according to the manufacturer’s instructions. qPCR was
performed using the StepOneReal-Time PCR system (ABI). Primer sequences
used for qPCR are listed in Table S1.
Measurement of Cytokines
In brief, 5 3 105 cells in a 24-well plate were either infected with VSV or Flu,
stimulated with LPS, or transfected with HCV 30UTR dsRNA or poly(I:C).
Twenty-four hours after infection, stimulation, or transfection, culture superna-Cell Host &tants were collected and analyzed for IFN-a, -b, and IL-6 production by ELISA.
Cytokine levels were measured in mouse serum obtained from the mouse tail
vein. ELISA kits for mouse IFN-a and -bwere purchased from PBL Biomedical
Laboratories. ELSA kit for mouse IL-6 was purchased from Invitrogen.
Preparation of Dendritic Cells and Macrophages
BM cells were prepared from the femur and tibia. The cells were cultured in
RPMI1640 medium supplemented with 10% FCS, 100 mM 2-Me, and
100 ng/ml human Flt3 ligand (Pepro Tech), and 10 ng/ml murine GM-CSF or
culture supernatant NIH 3T3 expressing M-CSF. After 6 days, cells were
collected and used as Flt3L-DC, GM-DC, or BM-Mf. In the case of GM-DC
or BM-Mf, the medium was changed every 2 days.
Native PAGE Analysis
Approximately 1 3 106 MEFs were infected with VSV at moi = 1 for 9 hr and
then lysed. Cell lysates in native PAGE sample buffer (62.5 mM Tris-HCl
[pH 6.8], 15% glycerol, and BPB) were separated using native PAGE and
then immunoblotted with anti-murine IRF3 antibody (Zymed).
Luciferase Assay
Expression plasmids for mouse RIG-I N-terminal CARDs, full-length RIG-I, or
full-lengthMDA5were constructed in pEF-BOS. The cDNA fragment encoding
the ORF of RIG-I or MDA5 was amplified by RT-PCR using total RNA prepared
from MEFs. The Riplet dRING mutant protein lacks 1–69 aa region. Wild-type
and mutant (Riplet dRING) Riplet-expression vectors were described previ-
ously (Oshiumi et al., 2009). Wild-type or Riplet/ MEFs were transiently
transfected in 24-well plates with reporter constructs containing the IFN-b
promoter and Renilla luciferase (internal control) together with the empty
vector (control), RIG-I CARDs, full-length RIG-I, or MDA5 expression vectors.
Twenty-four hours after transfection, cells were lysed and subjected to the
luciferase assay using the Dual-Luciferase Reporter Assay system (Promega).
Statistical Analyses
Statistical significance of differences between groups was determined by the
Student’s t test, and survival curves were analyzed by the log rank test using
Prism 4 for Macintosh software (GraphPad Sofware, Inc.). Chi-square good-
ness-of-fit tests and Student’s t tests were performed using MS-Excel
software and a chi-square distribution table.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article at doi:10.1016/j.
chom.2010.11.008.
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